Elite Pharmaceuticals (ELTP) AI Stock Analysis

• Market Cap: $537.14M
• Dividend Yield: N/A
• Average Volume (3M): 951.20K
• Price to Earnings (P/E): 89.1
• Beta (1Y): 1.63
• Revenue Growth: 72.67%
• EPS Growth: N/A
• Country: US
• Employees: 64
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): <0.01
• Shares Outstanding: 1,074,496,500
• 10 Day Avg. Volume: 753,540
• 30 Day Avg. Volume: 951,200
• PEG Ratio: 0.90
• Price to Book (P/B): 8.68
• Price to Sales (P/S): 5.53
• P/FCF Ratio: 94.25
• Enterprise Value/Market Cap: 1.24
• Enterprise Value/Revenue: 5.44
• Enterprise Value/Gross Profit: 10.32
• Enterprise Value/Ebitda: 25.53
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $0.54 ▲(8.40% Upside)

Elite Pharmaceuticals' strong revenue growth and improved operating profits are significant positives, but are offset by bearish technical indicators and high valuation concerns. Operational challenges and increased competition also weigh on the overall score.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and successful product launches, enhancing the company's competitive position.

FDA Approval

FDA approval for new products expands Elite's portfolio, potentially increasing market share and revenue streams in the long term.

Strong Operating Profit

The surge in operating profit reflects improved efficiency and successful cost management, supporting sustainable financial health.

Negative Factors

Increased Competition

Rising competition pressures margins and could erode market share, challenging Elite's profitability and growth prospects.

Higher G&A Costs

Rising administrative costs may strain profit margins, necessitating better cost control to maintain financial performance.

Cash Flow Consistency

Inconsistent cash flow generation could limit Elite's ability to fund operations and growth initiatives, affecting long-term stability.

Elite Pharmaceuticals Business Overview & Revenue Model

Company Description

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

How the Company Makes Money

Elite Pharmaceuticals generates revenue through multiple streams, including the sale of its proprietary and generic prescription products. The company earns money from product sales following the approval and commercialization of its formulations. Additionally, Elite Pharmaceuticals engages in partnerships and licensing agreements with larger pharmaceutical companies, allowing it to leverage their distribution networks and marketing capabilities. These collaborations often include milestone payments and royalties based on product sales, contributing significantly to its revenue. The company's focus on developing complex drug delivery systems enhances its competitive advantage and can lead to higher profit margins compared to standard generic drugs.

Elite Pharmaceuticals Financial Statement Overview

Summary

Elite Pharmaceuticals shows strong revenue growth and a robust balance sheet, but struggles with profitability and cash flow consistency. The net loss and fluctuating margins highlight operational challenges.

Income Statement

Elite Pharmaceuticals shows a strong revenue growth trajectory, with significant increases in revenue over the past few years. Despite the growth, the company faced a net loss in the latest period, impacting the net profit margin negatively. However, the gross profit margin remains robust, indicating efficient production. The variability in EBITDA margin over the years suggests operational challenges that need addressing.

Balance Sheet

The balance sheet reveals a healthy equity position with a favorable equity ratio, indicating strong financial resilience. The debt-to-equity ratio is manageable, suggesting moderate leverage, which poses less risk to financial stability. Return on equity has fluctuated significantly, reflecting volatility in profitability.

Cash Flow

Cash flow analysis indicates inconsistent free cash flow performance, with recent positive growth but past periods of negative free cash flow. The operating cash flow to net income ratio suggests that cash generation from operations can improve. The company's ability to convert net income into cash remains a challenge, as evidenced by the free cash flow to net income ratio.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	122.89M	84.04M	56.63M	34.16B	32.26M	25.38M
Gross Profit	64.71M	40.09M	26.36M	16.59B	14.80M	11.87M
EBITDA	26.17M	2.84M	2.52M	6.43M	6.49M	3.63M
Net Income	13.92M	-4.31M	20.11M	4.41B	8.90M	5.09M
Balance Sheet
Total Assets	117.25M	96.39M	83.65M	40.90M	35.15M	26.19M
Cash, Cash Equivalents and Short-Term Investments	26.62M	11.32M	7.11M	7.83M	8.54M	3.19M
Total Debt	3.32M	10.91M	11.74M	3.89M	2.78M	2.38M
Total Liabilities	44.99M	42.87M	26.07M	11.94M	9.93M	10.04M
Stockholders Equity	61.58M	53.52M	57.58M	28.96M	25.22M	16.15M
Cash Flow
Free Cash Flow	21.66M	4.93M	-4.09M	-2.40M	6.01M	2.86M
Operating Cash Flow	22.73M	7.46M	-3.28M	3.34M	6.51M	3.19M
Investing Cash Flow	-1.08M	-2.40M	-809.65K	-5.74M	-498.57K	-262.78K
Financing Cash Flow	-4.58M	-825.74K	3.39M	1.70M	-667.13K	-869.83K

Elite Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELTP, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.56, and below the 200-day MA of 0.56, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 39.40 is Neutral, neither overbought nor oversold. The STOCH value of 43.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELTP.

Elite Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	77 Outperform	$1.25B	12.02	14.84%	―	-0.03%	-27.66%
SIGA	73 Outperform	$449.00M	6.02	39.94%	―	-0.85%	-13.50%
ELTP	60 Neutral	$537.14M	89.11	25.58%	―	72.67%	―
AVDL	58 Neutral	$2.11B	―	-0.32%	―	79.88%	99.60%
AQST	56 Neutral	$730.80M	-8.52	―	―	-26.32%	-56.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ORGO	50 Neutral	$669.46M	―	0.30%	―	2.24%	-67.56%

Elite Pharmaceuticals Corporate Events

Elite Pharmaceuticals Reports 92% Revenue Growth in Q2

Elite Pharmaceuticals, Inc. reported significant financial growth for the second quarter of fiscal year 2026, ending September 30, 2025, with consolidated revenues reaching $36.3 million, marking a 92% increase from the same period in the previous fiscal year. This growth was largely driven by the successful launch of lisdexamfetamine products and strong performance of the Elite label product lines, resulting in an income from operations of $8.2 million, a 136% increase from the prior year.

Elite Pharmaceuticals Gains FDA Approval for Generic Drug

On November 12, 2025, Elite Pharmaceuticals announced it received FDA approval for a generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), used to treat Parkinson’s disease symptoms. This approval allows Elite to market the product under its Elite Laboratories label, potentially impacting the company’s market presence in the niche generic pharmaceutical sector, with the branded product and its equivalents having U.S. sales of $10 million for the twelve months ending September 2025.

Elite Pharmaceuticals to Release Q2 2026 Results Soon

Elite Pharmaceuticals announced that it will release its second quarter financial results for the fiscal year 2026 on November 14, 2025, with a conference call scheduled for November 17, 2025, to discuss these results and provide a business update. This announcement is significant for stakeholders as it provides insights into the company’s financial health and operational progress, potentially impacting its market positioning and investor relations.